Top News

India Investment News: Monday was a very positive day for the Indian stock market. The domestic market saw a strong rally, and both the Sensex and Nifty indices closed in the green. Meanwhile, another piece of good news for India came from the United States.

US pharmaceutical giant Eli Lilly and Co. has announced an investment of US$1 billion (about Rs 8,879 crore) in India. The company said the investment is aimed at strengthening its manufacturing and supply chain capabilities in India.

New centre to be built in Hyderabad

Eli Lilly Company announced that it will establish a new center in Hyderabad. This center will serve as the main hub for the company's manufacturing network across the country and provide high-quality technology and innovation services.

The company launched its weight loss and diabetes drug, "Mounjaro," in India earlier this year, and global demand for it is steadily increasing. Experts say Eli Lilly's investment is aimed at navigating the growing market for obesity and diabetes drugs, which could yield significant gains for the company in the future.

Telangana Chief Minister A. Revanth Reddy expressed his delight at Eli Lilly's investment, saying, "Lilly's investment in Hyderabad is a testament to the city's proven position as a trusted and emerging hub for global healthcare innovation." He added that this investment will not only increase employment opportunities in the state but also provide a new impetus to India's biotech and pharmaceutical industries.

Emphasis on local partnership and increasing production

Eli Lilly has announced that it will partner with local pharmaceutical companies in Telangana to expand drug production and distribution capacity, which it says will make obesity and diabetes medications more accessible and affordable in India.

"We are taking significant steps to expand our manufacturing and medicine supply capacity globally. This $1 billion investment in India is part of that strategy," said Patrick Johnson, Executive Vice President, Lilly International.

This investment could prove to be a major opportunity for India's healthcare and pharmaceutical sectors. Experts believe that the interest of companies like Eli Lilly in India confirms the country's pharmaceutical manufacturing capabilities, technology infrastructure, and global investment attractiveness.